Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (35)
  • Open Access

    REVIEW

    RP11-Derived Long Non-Coding RNAs in Hepatocellular Carcinoma: Hidden Treasures in Plain Sight

    Se Ha Jang1,2,#, Hyung Seok Kim3,#, Jung Woo Eun1,*

    Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.072240 - 30 December 2025

    Abstract Hepatocellular carcinoma (HCC) remains one of the most prevalent and lethal malignancies worldwide. Long non-coding RNAs (lncRNAs) have emerged as crucial regulators of gene expression and cancer progression, yet the functional diversity of RP11-derived lncRNAs—originally mapped to bacterial artificial chromosome (BAC) clones from the Roswell Park Cancer Institute—has only recently begun to be appreciated. This mini-review aims to systematically synthesize current findings on RP11-derived lncRNAs in HCC, outlining their genomic origins, molecular mechanisms, and biological significance. We highlight their roles in metabolic reprogramming, microRNA network modulation, and tumor progression, as well as their diagnostic and More >

  • Open Access

    ARTICLE

    Integrative Multi-Omics Analysis and Experiments Validation Identify COX5B as a Novel Therapeutic Target for Lung Adenocarcinoma

    Lv Ling1,#, Minying Lu2,#, Ling Ye3, Yuanhang Chen2, Sheng Lin2, Jun Yang2, Yu Rong2,*, Guixiong Wu4,*

    Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069889 - 30 December 2025

    Abstract Background: A significant proportion of patients still cannot benefit from existing targeted therapies and immunotherapies, making the search for new treatment strategies extremely urgent. In this study, we combined integrate public data analysis with experimental validation to identify novel prognostic biomarkers and therapeutic targets for lung adenocarcinoma (LUAD). Methods: We analyzed RNA and protein databases to assess the expression levels of cytochrome C oxidase 5B (COX5B) in LUAD. Several computational algorithms were employed to investigate the relationship between COX5B and immune infiltration in LUAD. To further elucidate the role of COX5B in LUAD, we utilized… More > Graphic Abstract

    Integrative Multi-Omics Analysis and Experiments Validation Identify COX5B as a Novel Therapeutic Target for Lung Adenocarcinoma

  • Open Access

    REVIEW

    RNA Expression Signatures in Glioblastoma: A Systematic Review of Tumour Biology and Therapeutic Targets

    Amber Hassan1, Badr Hafiz2, Taghreed Alsinani3, Rakan Bokhari4, Dahlia Mirdad5, Awab Tayyib5, Alaa Alkhotani6, Ahmad Fallata7, Iman Mirza8, Eyad Faizo9,10, Saleh Baeesa2, Huda Alghefari11, Maher Kurdi11,*

    Oncology Research, Vol.33, No.11, pp. 3293-3325, 2025, DOI:10.32604/or.2025.070031 - 22 October 2025

    Abstract Background: Glioblastoma (GBM) remains the most aggressive primary brain tumour in adults, marked by pronounced cellular heterogeneity, diffuse infiltration, and resistance to conventional treatment. In recent years, transcriptomic profiling has provided valuable insights into the molecular mechanisms that govern the progression of glioblastoma. This systematic review aims to synthesise the current literature on dysregulated gene expression in GBM, focusing on gene signatures associated with stemness, immune modulation, extracellular matrix remodelling, metabolic adaptation, and therapeutic resistance. Methods: We conducted a systematic search of PubMed, The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and the GlioVis… More >

  • Open Access

    REVIEW

    Reprogramming the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma: Therapeutic Targets and Innovations

    Bruno Špiljak1,#, Bojan Poposki2,#, Stjepanka Lešić3,*

    Oncology Research, Vol.33, No.11, pp. 3269-3292, 2025, DOI:10.32604/or.2025.068395 - 22 October 2025

    Abstract Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with high recurrence rates and prevalent resistance to therapeutic interventions. Tumor behavior is largely dependent on the tumor microenvironment (TME) that includes immune cells, stromal components, cancer-associated fibroblasts (CAFs), the extracellular matrix (ECM), and an associated cytokine network. In this review, we examine principal mechanisms of the tumorigenic transformation, encompassing immune checkpoint disruption, therapy resistance mediated through CAFs, the contribution of hypoxic niches, and several metabolic dependencies that hold potential as future targets. Novel therapeutics developed and/or repurposed, such as immune checkpoint inhibitors (ICIs),… More >

  • Open Access

    ARTICLE

    MRPL18 Promotes Breast Cancer Progression: Connecting Mitochondrial Ribosomal Protein to Immune Response

    Hailong Li1,#, Wen Ouyang2,#, Yiyin Long1, Yun Peng1, Ziyi Liu1, Qi Zhou1, Rong Xu1,*, Wei Du1,*

    Oncology Research, Vol.33, No.9, pp. 2549-2571, 2025, DOI:10.32604/or.2025.065050 - 28 August 2025

    Abstract Background: The study aimed to explore the clinical value of mitochondrial ribosomal protein L18 (MRPL18) in breast cancer. Methods: Multiple databases were used to validate the expression of MRPL18. The prognostic impact and predictive value of MRPL18 were evaluated by using predictive models. Protein-protein interaction (PPI) networks were constructed by using GeneMANIA. Enrichment analysis is used to explore the signaling pathway regulated by MRPL18. Cell counting kit-8 (CCK-8) assays, colony formation, migration assays, flow cytometry, and xenograft models were employed to evaluate the role of MRPL18 in tumor progression. The immune response of MRPL18 was More >

  • Open Access

    ARTICLE

    IL1A: a novel prognostic biomarker and potential therapeutic target for renal clear cell carcinoma

    JI ZENG1,2,3,#, XUETENG MENG1,3,#, YUAN ZHANG1,3, JUN LI1, TAOTAO MA1,3,4, CHENG HUANG1,3,*

    Oncology Research, Vol.33, No.7, pp. 1739-1755, 2025, DOI:10.32604/or.2025.061978 - 26 June 2025

    Abstract Background: Renal cell carcinoma (RCC) is a prevalent malignancy characterized by a rising incidence and significant mortality. Interleukins (ILs) are crucial in regulating immune cell trafficking and exhibit anti-tumor properties. However, limited research has explored the expression levels and prognostic significance of interleukins in RCC. Methods: In this comprehensive study, we performed a detailed analysis of interleukins in RCC patients using multiple bioinformatics tools, including Oncomine, UALCAN, GEPIA, Kaplan-Meier plotter, cBioPortal, GeneMANIA, TRRUST, STRING, and Linked Omics. Results: Our analysis demonstrated a significant upregulation in the transcriptional levels of IL4, IL7, IL15, IL16, IL23A, IL26, and… More >

  • Open Access

    ARTICLE

    Single-Cell Transcriptomic Profiling Reveals KRAS/TP53-Driven Neutrophil Reprogramming in Luad: A Multi-Gene Prognostic Model and Therapeutic Targeting of RHOV

    Yinghui Ye1,#, Yulou Luo2,#, Yutian Sun3, Yujie Zhang1, Jiaxin Lin4, Ziling Yang5, Anping Xu6,*, Bei Xue1,*

    Oncology Research, Vol.33, No.6, pp. 1383-1404, 2025, DOI:10.32604/or.2025.062584 - 29 May 2025

    Abstract Objectives: The tumorigenic progression of Lung adenocarcinoma (LUAD), the predominant NSCLC subtype, is predominantly driven by co-occurring mutations in KRAS proto-oncogene (KRAS)/Tumor protein p53 (TP53). However, their impact on tumor microenvironment (TME) heterogeneity, particularly neutrophil dynamics, remains poorly understood. This present study aims to elucidate how KRAS/TP53 mutations reprogram the TME and develop a neutrophil-centric prognostic signature for LUAD. Methods: Leveraging single-cell RNA sequencing data and transcriptome data, neutrophil subpopulations were identified using Seurat and CellChat R packages, with trajectory analysis via Monocle2 R package. High-dimensional weighted gene co-expression network analysis (hdWGCNA), univariate Cox regression,… More >

  • Open Access

    REVIEW

    Decoding CD24: Roles of chemoradiotherapy resistance and potential as therapeutic targets

    YU HONG1,#, YUNXIANG TANG1,#, WENYAN ZHOU1, HANYUE LUO2, LINLIN BU2, HUI QIU3,*, QIUJI WU3,*

    Oncology Research, Vol.33, No.6, pp. 1347-1361, 2025, DOI:10.32604/or.2025.059327 - 29 May 2025

    Abstract As a rising immune checkpoint on tumor cells, CD24 is closely related to tumorigenesis and progression. CD24 can directly regulate the malignant behavior of tumor cells and indirectly inhibit the function of immune cells in the meantime, which promotes the immune escape of tumor cells, induces cancer invasion and causes poor prognosis. The basic principle of cancer treatment is to induce cell death and inhibit cell survival. Resistance to chemoradiotherapy is a critical challenge in oncology, which limits the effectiveness of anti-cancer treatments. Many studies have shown a strong association between CD24 and chemoradiotherapy More >

  • Open Access

    COMMENTARY

    GlycoRNA: A new player in cellular communication

    HYUNG SEOK KIM*

    Oncology Research, Vol.33, No.5, pp. 995-1000, 2025, DOI:10.32604/or.2025.060616 - 18 April 2025

    Abstract The discovery of glycosylated RNA molecules, known as glycoRNAs, introduces a novel dimension to cellular biology. This commentary explores the transformative findings surrounding glycoRNAs, emphasizing their unique roles in cancer progression and the therapeutic opportunities they present. GlycoRNAs, through interactions with lectins and immune receptors, may contribute to tumor immune evasion. Moreover, the therapeutic potential of this emerging knowledge includes interventions targeting glycoRNA synthesis and modulation of associated signaling pathways. By highlighting these critical insights, this commentary aims to encourage the development of innovative strategies that could improve cancer prognosis and treatment. More >

  • Open Access

    REVIEW

    Involvement of ZBP1 in Cancer and Its Potential Therapeutic Target Effects

    Emmanuel Mago1, Jiayi Xu1, Dan Weng1,*, Yan Pan2,*

    BIOCELL, Vol.49, No.3, pp. 381-398, 2025, DOI:10.32604/biocell.2025.059432 - 31 March 2025

    Abstract Z-DNA binding protein 1 (ZBP1) has emerged as a critical player in cancer biology, functioning as a cytosolic nucleic acid sensor that triggers PANoptosis, a form of programmed cell death that integrates pyroptosis, apoptosis, and necroptosis. Although ZBP1 was initially recognized for its role in antiviral defense, recent research has highlighted its importance in the tumor microenvironment (TME), where it is essential for suppressing tumor growth and proliferation. This review explores the multifaceted role of ZBP1 in various cancer types, emphasizing its ability to detect Z-nucleic acids and double-stranded RNAs, leading to the initiation of… More >

Displaying 1-10 on page 1 of 35. Per Page